

CITATION REPORT

List of articles citing

Therapeutic strategies for rheumatoid arthritis

DOI: 10.1056/nejmra040226

New England Journal of Medicine, 2004, 350, 2591-602.

Source: <https://exaly.com/paper-pdf/37391337/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
451	Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. 1985 , 35, 562-5		24
450	Impacto de la enfermedad cardiovascular en los costos de hospitalizaci3n de pacientes con artritis reumatoidea.. 2004 , 24, 366		11
449	Rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2004 , 351, 1360-1; author reply 1360-1	59.2	6
448	Assessment of drug interactions relevant to pharmacodynamic indirect response models. 2004 , 31, 345-80		37
447	El tratamiento del lupus eritematoso sist3mico. Utilizaci3n de antipal3dicos en enfermedades inflamatorias. 2004 , 204, 565-566		
446	Anticytokine therapies in rheumatoid arthritis: from the pipette to the patient. 2004 , 1, 293-297		1
445	Augmented heme oxygenase-1 induces prostaglandin uptake via the prostaglandin transporter in micro-vascular endothelial cells. 2004 , 323, 1299-305		6
444	The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis. 2005 , 23, 289-98		14
443	New rheumatoid arthritis treatments. 2005 , 19, 197-204; quiz 205-6		1
442	New Rheumatoid Arthritis Treatments. 2005 , 30, 28-39		
441	Efficiency of combined methotrexate/chloroquine therapy in adjuvant-induced arthritis. 2005 , 19, 479-89		14
440	Host response modulation in the management of periodontal diseases. 2005 , 32 Suppl 6, 108-29		173
439	The need for tighter rheumatoid arthritis control in a South African public health care center. 2005 , 35, 122-31		13
438	Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis. 2005 , 52, 1929-40		56
437	Antigen microarray profiling of autoantibodies in rheumatoid arthritis. 2005 , 52, 2645-55		234
436	Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids. 2005 , 24, 612-4		7
435	[Rheumatoid arthritis--pearls and myths]. 2005 , 62, 269-71		

434	New Rheumatoid Arthritis Treatments. 2005 , 30, 29-39	1
433	26 Rheumatologische Erkrankungen. 2005 ,	
432	New Rheumatoid Arthritis Treatments. 2005 , 30, 39-41	
431	Folic acid supplementation during methotrexate treatment: nonsense?. 2005 , 44, 563-4	2
430	Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis. 2005 , 10, 299-310	16
429	[Rheumatoid arthritis]. 2005 , 130, 1761-8; quiz 1769-72	3
428	Drug delivery strategies for cathepsin inhibitors in joint diseases. 2005 , 2, 1015-28	19
427	TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. 2005 , 174, 485-90	175
426	A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. 2005 , 5, 519-29	4
425	Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. 2005 , 64, 1731-6	218
424	B cell reductive therapy in the treatment of autoimmune diseases: a focus on monoclonal antibody treatment of rheumatoid arthritis. 2005 , 10, 521-7	2
423	CE Test: New Rheumatoid Arthritis Treatments. 2005 , 30, 39-41	2
422	First efficacy and safety results with the antibody containing leukocyte inhibition module in cardiac surgery patients with neutrophil hyperactivity. 2005 , 51, 144-7	10
421	Traitement par anticorps anti-IgE de l'asthme allergique difficile à contrôler. 2005 , 22, 983-990	5
420	Biological drug use: US perspectives on indications and monitoring. 2005 , 64 Suppl 4, iv18-23	37
419	Rituximab treatment of refractory rheumatoid arthritis. 2005 , 39, 2091-5	12
418	Suppressive effect of AIF, a water extract from three herbs, on collagen-induced arthritis in mice. 2005 , 5, 1365-72	15
417	Pathophysiology and management of arthritis. 2005 , 35, 1073-91, v	19

416	Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. 2005 , 116, 8-16	94
415	[Antimalarials in systemic diseases]. 2005 , 205, 230-2	6
414	Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. 2005 , 7, R862-7	64
413	Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. 2005 , 7, R592-603	52
412	Anakinra in the treatment of rheumatic disease. 2006 , 2, 331-40	13
411	De novo design TNF-alpha antagonistic peptide based on the complex structure of TNF-alpha with its neutralizing monoclonal antibody Z12. 2006 , 125, 57-63	10
410	PET Imaging of Arthritis. 2006 , 1, 131-9	5
409	Treatment of rheumatoid arthritis. 2006 , 63, 2451-65	118
408	Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. 2006 , 3, 717-25	75
407	Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease. 2006 , 367, 62-8	19
406	The endocannabinoid system as an emerging target of pharmacotherapy. 2006 , 58, 389-462	1993
405	Fusion protein of CDR mimetic peptide with Fc inhibit TNF-alpha induced cytotoxicity. 2006 , 43, 660-6	16
404	A European perspective on the challenges of managing psoriasis. 2006 , 54, S81-4	19
403	Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. 2006 , 16, 223-36	50
402	Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis. 2006 , 184, 122-5	13
401	Emerging new therapies in rheumatoid arthritis: what's next for the patient?. 2006 , 29, 326-37	5
400	The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. 2006 , 48, 135-48	63
399	Intravenous application of omega-3 fatty acids in patients with active rheumatoid arthritis. The ORA-1 trial. An open pilot study. 2006 , 41, 29-34	33

398	Proteomic biomarkers for autoimmune disease. 2006 , 6, 4100-5	53
397	Clinical approach to patients with joint disease: importance of distinguishing inflammatory from non-inflammatory conditions. 2006 , 9, 11-17	1
396	Biological therapies for rheumatoid arthritis: beyond TNF- α blockade. 2006 , 9, 200-205	1
395	Effects of combination of melatonin and dexamethasone on acute lung injury in a mice model of carrageenan-induced pleurisy. 2006 , 41, 228-37	18
394	Résultats cliniques du traitement anti-TNF-alpha dans la polyarthrite rhumatoïde traitée en ville. 2006 , 73, 47-52	1
393	Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community. 2006 , 73, 51-6	15
392	Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. 2006 , 73, 388-95	105
391	New therapeutics that treat rheumatoid arthritis by blocking T-cell activation. 2006 , 11, 952-6	12
390	Satoyoshi syndrome: a rare multisystemic disorder requiring systemic and symptomatic treatment. 2006 , 28, 300-4	15
389	Regulation of matrix metalloproteinase expression by dynamic tensile strain in rat fibrochondrocytes. 2006 , 14, 264-72	52
388	The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. 2006 , 54, 54-9	69
387	Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. 2006 , 54, 557-68	35
386	Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. 2006 , 54, 1856-66	205
385	How should best strategy and tight control be translated into clinical practice? Comment on the article by Goekoop-Ruiterman et al. 2006 , 54, 2338-9; author reply 2339	1
384	Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. 2006 , 54, 2402-14	52
383	The benefit of low-dose glucocorticoid treatment in early rheumatoid arthritis may outweigh the risk: comment on the editorial by Harris. 2006 , 54, 2031-2; author reply 2032	4
382	IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. 2006 , 54, 3163-73	67
381	British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (The first 2 years). 2006 ,	5

380	Are rheumatologists' treatment decisions influenced by patients' age?. 2006 , 45, 1555-7		48
379	Medical therapy: where are we now?. 2006 , 63, S11-8		3
378	Minocycline-induced vasculitis fulfilling the criteria of polyarteritis nodosa. <i>Modern Rheumatology</i> , 2006 , 16, 256-259	3.3	13
377	Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. 2006 , 65, 753-9		145
376	TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. 2007 , 178, 693-701		91
375	Antiarthritic effects of relaxin, in combination with estrogen, in rat adjuvant-induced arthritis. 2007 , 322, 887-93		23
374	P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. 2007 , 11, 1103-17		66
373	Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis. 2007 , 66, 1289-95		11
372	Therapeutic Plasma Exchange. 2007 , 738-764		2
371	Role of cathepsin K in normal joints and in the development of arthritis. 2007 , 8, 315-23		83
370	Lessons from a genomewide association study of rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2007 , 357, 1250-1	59.2	13
369	Pulmonary manifestations of rheumatoid arthritis. 2007 , 28, 430-40		32
368	Interobserver agreement in two- and three-dimensional power Doppler sonographic assessment of synovial vascularity during anti-inflammatory treatment in patients with rheumatoid arthritis. 2007 , 28, 409-15		20
367	Targeting of the transcription factor STAT4 by antisense phosphorothioate oligonucleotides suppresses collagen-induced arthritis. 2007 , 178, 3427-36		50
366	Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside. 2007 , 3, 26-34		79
365	Update on abatacept: a selective costimulation modulator for rheumatoid arthritis. 2007 , 41, 1153-62		29
364	Somatostatin Involvement in Rheumatoid Arthritis. 2007 , 3, 31-36		
363	Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). 2007 , 66, 1443-9		372

- 362 Clinician's comment on the management of pain in arthritis. **2007**, 26, 657-9 6
- 361 A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis. **2007**, 30, 96-104; quiz 120
- 360 Pharmacogenetics in the future treatment of rheumatology. **2007**, 2, 337-339
- 359 Artritis reumatoide: formas de presentaci3n, diagn3stico y tratamiento actual. **2007**, 14, 126-132 1
- 358 [Reduction in time until first treatment with disease modifying treatment in patients with rheumatoid arthritis]. **2007**, 3, 245-50 11
- 357 Gait analysis in a murine model of collagen-induced arthritis. **2007**, 9, R123 50
- 356 Remission by composite scores in rheumatoid arthritis: are ankles and feet important?. **2007**, 9, R72 28
- 355 Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. **2007**, 9, R2 116
- 354 Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. **2008**, 47, 535-41 32
- 353 Reduction in Time Until First Treatment With Disease Modifying Treatment in Patients With Rheumatoid Arthritis. **2007**, 3, 245-250
- 352 Classification of rheumatoid arthritis status with candidate gene and genome-wide single-nucleotide polymorphisms using random forests. **2007**, 1 Suppl 1, S62 23
- 351 The BeSt way to treat early rheumatoid arthritis?. **2007**, 146, 459-60 5
- 350 Autoimmune and Inflammatory Disorders. **2007**, 1155-1184
- 349 Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458. **2007**, 56, 850-60 24
- 348 B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. **2007**, 56, 1417-23 162
- 347 Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB. **2007**, 56, 2255-66 79
- 346 Small-vessel and medium-vessel vasculitis. **2007**, 57, 1552-9 18
- 345 It is the best of times; it is the worst of times: is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues. **2007**, 56, 3884-6 7

344	Biomechanical strain regulates TNFR2 but not TNFR1 in TMJ cells. 2007 , 40, 1541-9	4
343	Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. 2007 , 26, 1237-54	110
342	The snake venom metalloproteinase BaP1 induces joint hypernociception through TNF-alpha and PGE2-dependent mechanisms. 2007 , 151, 1254-61	31
341	Anti-inflammatory effects of BT-201, an n-butanol extract of Panax notoginseng, observed in vitro and in a collagen-induced arthritis model. 2007 , 26, 785-91	40
340	Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. 2007 , 12, 125-31	52
339	[Cooperation between primary care physicians and rheumatologists in Lower Saxony. Results of a survey of primary care physicians]. 2007 , 66, 142, 144-51	0
338	Neutrophils-derived peroxynitrite contributes to acute hyperalgesia and cell influx in zymosan arthritis. 2007 , 374, 265-73	38
337	Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis. 2007 , 27, 531-6	8
336	The metabolic changes caused by dexamethasone in the adjuvant-induced arthritic rat. 2007 , 302, 87-98	17
335	Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis. 2008 , 25, 2910-9	90
334	Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease. 2008 , 8, 278-87	10
333	The comparative effectiveness of methotrexate and anti-tumor necrosis factor therapy in psoriatic arthritis. 2008 , 10, 295-6	
332	Hepatitis B virus (HBV) and autoimmune disease. 2008 , 34, 85-102	84
331	A pilot study of acupuncture as adjunctive treatment of rheumatoid arthritis. 2008 , 27, 627-35	30
330	Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial. 2008 , 9, 6	19
329	Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. 2008 , 59, 785-93	81
328	Bone-protective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis. 2008 , 16, 1243-51	66
327	Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. 2008 , 10, R14	113

326	Therapy in Neuromuscular Diseases. 2008 , 77-92		
325	Polyarthrite rhumatoïde, mise au point sur le traitement et prise en charge anesthésique. 2008 , 12, 398-407		
324	Prise en charge d'un patient atteint de polyarthrite rhumatoïde pendant et après une anesthésie. 2008 , 12, 167-170		
323	The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. 2008 , 17, 349-59		76
322	Psychologic interventions and lifestyle modifications for arthritis pain management. 2008 , 34, 351-68		41
321	Differences between rheumatology attending physicians and training residents in the management of rheumatoid arthritis in Spain. 2008 , 37, 419-26		8
320	Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States. 2008 , 26, 395-408		24
319	Productivity cost model of the treatment of rheumatoid arthritis with abatacept. 2008 , 11, 3-21		8
318	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. <i>Modern Rheumatology</i> , 2008 , 18, 460-464	3-3	41
317	Nutrition and Rheumatic Disease. 2008 ,		5
316	N-of-1 trials of expensive biological therapies: a third way?. 2008 , 168, 1030-3		18
315	The interleukin-17 receptor plays a gender-dependent role in host protection against Porphyromonas gingivalis-induced periodontal bone loss. 2008 , 76, 4206-13		66
314	Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy. 2008 , 37, 306-9		6
313	Chapter 10 Gastrointestinal Manifestations of Rheumatoid Arthritis. 2008 , 109-117		2
312	Teriparatide or alendronate in glucocorticoid-induced osteoporosis. <i>New England Journal of Medicine</i> , 2008 , 358, 1302; author reply 1303-4	59.2	1
311	The Development of Novel Therapies for Rheumatoid Arthritis. 2008 , 18, 723-738		129
310	Chronic inflammatory pain and the neurovascular unit: a central role for glia in maintaining BBB integrity?. 2008 , 14, 1625-43		52
309	Association Between Sharp's Radiographic Index and Acute Phase Reactants in Rheumatoid Arthritis. 2008 , 27, 447-453		

308	Oral administration of highly oligomeric procyanidins of Jatoba reduces the severity of collagen-induced arthritis. 2008 , 72, 1781-8	15
307	Increased biological half-life of aerosolized liposomal recombinant human Cu/Zn superoxide dismutase in pigs. 2008 , 21, 281-90	23
306	Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. 2008 , 18, 1041-9	36
305	Histone deacetylase inhibitors: new hope for rheumatoid arthritis?. 2008 , 14, 803-20	56
304	Return to work of individuals with arthritis: A review of job performance and retention. 2009 , 30, 121-131	8
303	Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis. 2009 , 183, 3770-7	44
302	Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. 2009 , 68, 1146-52	49
301	Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?. 2009 , 48, 1247-53	5
300	Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. 2009 , 9, 1463-75	28
299	Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis. 2009 , 138, 225-34	36
298	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. 2009 , 8, 274-80	89
297	Current treatments of chronic immune-mediated demyelinating polyneuropathies. 2009 , 39, 563-78	59
296	Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. 2009 , 60, 12-21	119
295	The DERA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies. 2009 , 60, 698-707	25
294	Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. 2009 , 60, 669-77	47
293	Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. 2009 , 60, 3196-206	243
292	The relationship between quality of life and aerobic fitness in patients with rheumatoid arthritis. 2009 , 28, 685-91	17
291	Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. 2009 , 28, 931-46	83

290	Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis. 2009 , 28, 1135-9	12
289	Preliminary study on the immunologic background of good clinical outcome in rheumatoid arthritis patients after one month therapy with leflunomide. 2009 , 29, 937-46	3
288	Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis. 2009 , 29, 431-6	23
287	Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. 2009 , 8, 150-62	7
286	Protective effect of geranylgeranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal model. 2009 , 9, 45	25
285	PS3, a semisynthetic beta-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions. 2009 , 129, 1192-202	23
284	Blocking interleukin-1 in rheumatic diseases. 2009 , 1182, 111-23	73
283	Effects of nitric oxide on neutrophil influx depends on the tissue: role of leukotriene B4 and adhesion molecules. 2009 , 156, 818-25	17
282	Effects of linear polarized infrared light irradiation on the transcriptional regulation of IL-8 expression in IL-1beta-stimulated human rheumatoid synoviocytes involves phosphorylation of the NF-kappaB RelA subunit. 2009 , 94, 164-70	9
281	A multicenter clinical trial in rheumatoid arthritis comparing silicone metacarpophalangeal joint arthroplasty with medical treatment. 2009 , 34, 815-23	64
280	Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. 2009 , 124, 1141-9; quiz 1150-1	107
279	Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. 2009 , 23, 111-24	58
278	Glucocorticoides en la artritis reumatoide. 2009 , 10, 44-47	
277	B cell depletion in early rheumatoid arthritis: a new concept in therapeutics. 2009 , 1173, 729-35	5
276	Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. 2009 , 11, R76	84
275	Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. 2009 , 26, 273-93	19
274	Effect of immunosuppression on patients undergoing bariatric surgery. 2009 , 5, 339-45	12
273	Folate receptor α a novel target for therapeutic intervention in rheumatoid arthritis?. 2009 , 4, 109-113	3

272 Specialized Therapeutic Hemapheresis and Phlebotomy. 652-680

271	Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. 2009 , 73, 977-85	119
270	Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. 2009 , 151, 229-40, W49-51	157
269	Pharmacogenetics in treatment of rheumatoid arthritis. 2010 , 16, 164-75	26
268	Clinical efficacy of TNF-inhibitors: an update. 2010 , 5, 101-115	2
267	The older rheumatoid arthritis patients: who are they and how should they be treated?. 2010 , 6, 533-549	1
266	RA: overview of recommended diagnosis and drug treatment. 2010 , 21, 18-33	3
265	Beyond oncology--application of HPMA copolymers in non-cancerous diseases. 2010 , 62, 258-71	32
264	State-of-the-art: rheumatoid arthritis. 2010 , 69, 1898-906	215
263	Validity and responsiveness of the Michigan Hand Questionnaire in patients with rheumatoid arthritis: a multicenter, international study. 2010 , 62, 1569-77	68
262	Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies. 2010 , 62, 1624-32	24
261	The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. 2010 , 62, 3277-88	41
260	Socio-demographic and clinical aspects of rheumatoid arthritis. 2009 , 86, 204-11	8
259	Analgesic use in the elderly: the "pain" and simple truth: comment on "The comparative safety of analgesics in older adults with arthritis". 2010 , 170, 1976-8	9
258	Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. 2010 , 67, 1281-7	27
257	Radiographic progression of cervical lesions in patients with rheumatoid arthritis receiving infliximab treatment. <i>Modern Rheumatology</i> , 2010 , 20, 273-279	3-3 11
256	Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. 2010 , 69, 1022-8	66
255	Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. 2010 , 49, 733-40	30

254	Rheumatoid arthritis pharmacogenomics. 2010 , 11, 617-9	10
253	Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?. 2010 , 69, 387-93	127
252	Patologĳ osteomuscular en geriatriĳ. 2010 , 10, 4282-4290	
251	Healing the Syk through kinase inhibitors. <i>New England Journal of Medicine</i> , 2010 , 363, 1362-4	59.2 16
250	Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis. 2010 , 12, R105	47
249	An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant-induced arthritis. 2011 , 44, 471-82	34
248	Stress and autoimmunity. 2011 , 31, 1-18	74
247	Outcomes research in rheumatoid arthritis. 2011 , 27, 115-26	8
246	Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis. 2011 , 44, 465-70	67
245	Nontumoral lesions of the craniocervical junction. 2011 , 443-455	
244	Pathology and surgery around the vertebral artery. 2011 ,	4
243	Inhibitory effects of a traditional Chinese herbal formula TBL-II on type II collagen-induced arthritis in mice. 2011 , 134, 399-405	13
242	Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. 2011 , 13, R204	33
241	Interferon beta to treat multiple sclerosis. 300-314	
240	Combination therapy in multiple sclerosis. 547-556	
239	Application of Monoclonal Antibody Therapies in Autoimmune Diseases. 2011 ,	
238	Managed Care Strategies for Improving Patient Outcomes in Rheumatoid Arthritis. 2011 , 17, 1-29	
237	Microglial response to viral challenges: every silver lining comes with a cloud. 2011 , 16, 2187-205	29

236	Assessment of disease activity and treatment outcomes in rheumatoid arthritis. 2011 , 17, S09-13	24
235	New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade. 2011 , 34, 107-15	1
234	Doppler ultrasonography for assessing rheumatoid arthritis. 2011 , 6, 47-55	1
233	Juvenile idiopathic arthritis: can you recognize this complex diagnosis?. 2011 , 24, 22-7	2
232	New applications of imaging techniques for monitoring progression of rheumatoid arthritis and predicting outcome. 2011 , 3, 107-122	3
231	Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. 2011 , 28, 776-87	76
230	Sphingosine-1-phosphate: a potential therapeutic target for rheumatoid arthritis. 2011 , 38, 4225-30	22
229	Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. 2011 , 30, 303-12	29
228	[Therapeutic strategies in rheumatoid arthritis]. 2011 , 52, 645-56	3
227	Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis. 2011 , 112, 107-17	94
226	Injectable hyaluronic acid-tyramine hydrogels for the treatment of rheumatoid arthritis. 2011 , 7, 666-74	95
225	Geriatric Rheumatology. 2011 ,	6
224	Randomised double-blind trial of combination antibiotic therapy in rheumatoid arthritis. 2011 , 2011, 585497	1
223	Time to treatment for new patients with rheumatoid arthritis in a major metropolitan city. <i>Journal of Rheumatology</i> , 2011 , 38, 1282-8	4.1 52
222	Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. 2011 , 50, 1320-30	29
221	Polyarthrite rhumatoïde. 2011 , 1171-1176	
220	Prädiktive Bedeutung von Autoantikörpern/Predictive relevance of autoantibodies. 2011 , 35, 363-373	1
219	A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. 2012 , 71, 845-50	119

218	Emerging issues in pharmacological management of rheumatoid arthritis: results of a national needs assessment survey identifying practice variations for the development of Canadian Rheumatology Association clinical practice recommendations. <i>Journal of Rheumatology</i> , 2012 , 39, 1555-8	4.1	8
217	Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists. 2012 , 71, 1680-5		15
216	[How early would we really administer biologics?]. 2012 , 71, 838-9		1
215	Activity study of a hydroxynaphthoquinone fraction from <i>Arnebia euchroma</i> in experimental arthritis. 2012 , 83, 1226-37		23
214	Scorpio and Scolopendra attenuate inflammation and articular damage in rats with collagen-induced arthritis. 2012 , 141, 603-7		8
213	Advances in the treatment of inflammatory arthritis. 2012 , 26, 251-61		33
212	Mutated citrullinated vimentin antibodies in rheumatoid arthritis. 2012 , 413, 66-73		16
211	Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion. 2012 , 12, 68		19
210	Short time administration of antirheumatic drugs - methotrexate as a strong inhibitor of osteoblast's proliferation in vitro. 2012 , 8, 26		14
209	Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2012 , 367, 508-19	59.2	658
208	Characterization of immunologically active drugs in a novel organotypic co-culture model of the human gut and whole blood. 2012 , 14, 722-8		12
207	Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. 2012 , 5, 69-89		60
206	Anti-inflammatory effects of polyphenolic-enriched red raspberry extract in an antigen-induced arthritis rat model. 2012 , 60, 5755-62		63
205	Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity. 2012 , 14, R57		37
204	Perfil dos usuários de anticitocinas disponibilizadas pelo Sistema Único de Saúde no estado do Paraná para o tratamento da artrite reumatoide. 2012 , 52, 208-213		2
203	Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis. 2012 , 71, 1733-40		89
202	Effect of triptolide on T-cell receptor beta variable gene mRNA expression in rats with collagen-induced arthritis. 2012 , 295, 922-7		21
201	Inhibitory effect of anethole in nonimmune acute inflammation. 2013 , 386, 331-8		47

200	Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?. 2013 , 11, 17		50
199	Enhancement of placenta growth factor expression by oncostatin M in human rheumatoid arthritis synovial fibroblasts. 2013 , 228, 983-90		14
198	Combination therapy of dexamethasone with epigallocatechin enhances tibiotarsal bone articulation and modulates oxidative status correlates with cartilage cytokines expression in the early phase of experimental arthritis. 2013 , 698, 444-54		6
197	The effectiveness of Echinacea extract or composite glucosamine, chondroitin and methyl sulfonyl methane supplements on acute and chronic rheumatoid arthritis rat model. 2013 , 29, 187-201		15
196	The histone deacetylase inhibitors MS-275 and SAHA suppress the p38 mitogen-activated protein kinase signaling pathway and chemotaxis in rheumatoid arthritic synovial fibroblastic E11 cells. 2013 , 18, 14085-95		21
195	Anti-arthritic effects of clematichinenoside (AR-6) on PI3K/Akt signaling pathway and TNF- α associated with collagen-induced arthritis. 2013 , 51, 13-22		33
194	Quantitative Structure-Activity Relationship Model of Lenalidomide Analogues as TNF-Inhibitors. 2013 ,		
193	Exercise prescription in the management of rheumatoid arthritis. 2013 , 55, 345-349		2
192	Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. <i>Modern Rheumatology</i> , 2013 , 23, 742-751	3-3	23
191	Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. 2013 , 14, 63-73		17
190	Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. 2013 , 16, 385-93		63
189	Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway. 2013 , 161, 89-98		62
188	Intra-articular drug delivery from an optimized topical patch containing teriflunomide and lornoxicam for rheumatoid arthritis treatment: does the topical patch really enhance a local treatment?. 2013 , 169, 73-81		44
187	A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. 2013 , 191, 4969-78		59
186	Pharmacokinetics and bioequivalence evaluation of leflunomide tablets in Korean healthy volunteers. 2013 , 63, 633-8		3
185	Protective efficacy of N-(2-hydroxyphenyl) acetamide against adjuvant-induced arthritis in rats. 2013 , 2013, 635143		7
184	Osteoarthritis: detection, pathophysiology, and current/future treatment strategies. 2013 , 32, 25-36; quiz 37-8		15
183	Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis. 2013 , 2013, 313858		23

182	The nurse's role in addressing unmet treatment and management needs of patients with rheumatoid arthritis: Delphi-based recommendations. 2013 , 24, 66-76	9
181	Predictors of pain for patients with early inflammatory polyarthritis. 2013 , 65, 992-9	9
180	Michigan Hand Outcomes Questionnaire in rheumatoid arthritis patients: relationship with disease activity, quality of life, and handgrip strength. 2013 , 26, 467-73	11
179	Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies. 2013 , 14, 332	14
178	Comparative genome-wide gene expression analysis of rheumatoid arthritis and osteoarthritis. 2013 , 12, 3136-45	4
177	Surgical procedures for rheumatoid arthritis. 746-750	
176	Clinical Characteristics of Korean Rheumatoid Arthritis Patients with Indications for TNF-Blocker. 2014 , 21, 1	
175	Cross-cultural adaptation and validation of the Michigan Hand Outcomes Questionnaire (MHQ) for Brazil: validation study. 2014 , 132, 339-347	9
174	Interstitial lung abnormalities in rheumatoid arthritis are common and important. 2014 , 146, 8-10	7
173	Rheumatoid Arthritis. 2014 , 11, 53-64	2
172	Extended blood circulation and joint accumulation of a p(HPMA-co-AzMA)-based nanoconjugate in a murine model of rheumatoid arthritis. 2014 , 2, 29	2
171	Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. 2014 , 16, R94	78
170	The Study of Pyridazine Compounds on Prostanoids: Inhibitors of COX, cAMP Phosphodiesterase, and TXA2Synthase. 2014 , 2014, 1-16	5
169	Bioinformatic analysis to find small molecules related to rheumatoid arthritis. 2014 , 17, 71-7	2
168	Chemical characterization of a red raspberry fruit extract and evaluation of its pharmacological effects in experimental models of acute inflammation and collagen-induced arthritis. 2014 , 5, 3241-51	27
167	Design and evaluation of a novel transdermal patch containing diclofenac and teriflunomide for rheumatoid arthritis therapy. 2014 , 9, 251-259	24
166	Evolutionary Biology: Genome Evolution, Speciation, Coevolution and Origin of Life. 2014 ,	4
165	Comparative effectiveness of cycling of tumor necrosis factor- α inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-inhibitor using a Bayesian approach. 2014 , 37, 662-70	32

164	Tofacitinib versus methotrexate in rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2014 , 370, 2377-86	59.2	495
163	Animal models of human disease: inflammation. 2014 , 87, 121-30		68
162	Predicting and verifying outcome of Tripterygium wilfordii Hook F. based therapy in rheumatoid arthritis: from open to double-blinded randomized trial. 2015 , 5, 9700		31
161	MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients. 2015 , 10, 216		14
160	Herb Network Analysis for a Famous TCM Doctor's Prescriptions on Treatment of Rheumatoid Arthritis. 2015 , 2015, 451319		14
159	Inhibitory Effects for Rheumatoid Arthritis of Dietary Supplementation with Resveratrol in Collagen-induced Arthritis. 2015 , 22, 93		10
158	Rheumatoid lung. 2015 , 2015,		
157	Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis. 2015 , 30, 227-30		7
156	Anti-arthritic activity of Fu-Fang-Lu-Jiao-Shuang on collagen-induced arthritis in Balb/c mice and its underlying mechanisms. 2015 , 11, 242-9		7
155	Depressive symptoms predict future simple disease activity index scores and simple disease activity index remission in a prospective cohort of patients with early inflammatory polyarthritis. 2015 , 54, 2205-14		11
154	Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. 2015 , 17, 307		36
153	FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. 2015 , 16, 373-81		18
152	Haptoglobin- α_1 , α_2 , vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis. 2015 , 17, 45		17
151	Effects of Alpha-Lipoic Acid Supplementation on Inflammatory Biomarkers and Matrix Metalloproteinase-3 in Rheumatoid Arthritis Patients. 2015 , 34, 310-7		18
150	Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea. 2015 , 37, 1662-76.e2		16
149	Treatment of rheumatoid arthritis: Unraveling the conundrum. 2015 , 65, 1-18		73
148	Characteristics of traditional Chinese medicine use in patients with rheumatoid arthritis in Taiwan: A nationwide population-based study. 2015 , 176, 9-16		48
147	Monoclonal Antibodies as Therapeutic Agents. 2016 , 157-196		1

146	Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile. 2016 , 11, 22-34	7
145	Future Biological and Chemical Weapons. 2016 , 489-498	5
144	Long-term exposure to PGE2 causes homologous desensitization of receptor-mediated activation of protein kinase A. 2016 , 13, 181	6
143	Soy milk consumption, markers of inflammation and oxidative stress in women with rheumatoid arthritis: A randomised cross-over clinical trial. 2016 , 73, 139-145	11
142	Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis. 2016 , 46, 246-252	52
141	Steroidal Nanodrugs Based on Pegylated Nanoliposomes Remote Loaded with Amphipathic Weak Acids Steroid Prodrugs as Anti-Inflammatory Agents. 2016 , 603-632	
140	Clinical Management of the Rheumatoid Hand, Wrist, and Elbow. 2016 ,	1
139	Protective effects of a blueberry extract in acute inflammation and collagen-induced arthritis in the rat. 2016 , 83, 1191-1202	28
138	Liposomal nano-drugs based on amphipathic weak acid steroid prodrugs for treatment of inflammatory diseases. 2016 , 24, 805-820	7
137	Albumin-Oxanorbornadiene Conjugates Formed ex Vivo for the Extended Circulation of Hydrophilic Cargo. 2016 , 11, 2320-7	13
136	Stellenwert der Anämie bei rheumatoider Arthritis. 2016 , 15, 96-99	0
135	Serum levels of 14-3-3 σ protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis. 2016 , 18, 37	24
134	Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. 2016 , 75, 1057-64	101
133	[Pneumocystosis in non-HIV-infected immunocompromised patients]. 2016 , 37, 327-36	9
132	Current Treatment Outcomes Among Patients with Rheumatoid Hand and Wrist Deformities. 2016 , 53-60	
131	A semi-synthetic natural product blocks collagen induced arthritis by preferentially suppressing the production of IL-6. 2016 , 33, 63-9	1
130	The immunomodulatory properties of human bone marrow-derived mesenchymal stromal cells are defined according to multiple immunobiological criteria. 2016 , 65, 501-10	21
129	Effect of Sesamin Supplementation on Cardiovascular Risk Factors in Women with Rheumatoid Arthritis. 2016 , 35, 300-7	27

128	Improved survival in rheumatoid arthritis: a general population-based cohort study. 2017 , 76, 408-413	63
127	Is rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis. 2017 , 33, 1901-1908	17
126	Inflammation and pharmacokinetics: potential implications for HIV-infection. 2017 , 13, 641-650	18
125	p-Coumaric acid, a dietary polyphenol ameliorates inflammation and curtails cartilage and bone erosion in the rheumatoid arthritis rat model. 2017 , 43, 698-717	34
124	A Haystack Heuristic for Autoimmune Disease Biomarker Discovery Using Next-Gen Immune Repertoire Sequencing Data. 2017 , 7, 5338	3
123	Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis. 2017 , 18, 945-953	4
122	Sophocarpine suppress inflammatory response in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. 2017 , 28, 120-126	14
121	70 years of progress: history of the Rheumatism Society of the District of Columbia, 1946-2016. 2017 , 20, 2258-2261	
120	In vivo anti-inflammatory activity of Liquidambar formosana Hance infructescence extract. 2017 , 16, 2403-2410	6
119	Gastrointestinal Manifestations of Rheumatoid Arthritis. 2017 , 333-348	
118	Clinical Uses of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Potential Benefits of NSAIDs Modified-Release Preparations. 2017 , 1-29	9
117	Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor. 2018 , 26, 1495-1510	5
116	Design, synthesis and evaluation of ()-3-(7-(methyl(7-pyrrolo[2,3]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor. 2018 , 9, 477-489	3
115	Heterogeneity in the determinants of length of stay across middle age and senior age groups in thermal tourism. 2018 , 35, 531-540	10
114	Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis. 2018 , 21, 3-21	6
113	Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan. <i>Modern Rheumatology</i> , 2018 , 28, 48-57	3-3 9
112	Licochalcone A activates Keap1-Nrf2 signaling to suppress arthritis via phosphorylation of p62 at serine 349. 2018 , 115, 471-483	39
111	Suppressive effects of Wang-Bi Tablet on adjuvant-induced arthritis in rats via NF- κ B and STAT3 signaling pathways. 2018 , 42, 1666-1674	6

110	Efficacy and Safety of Hepatitis B Vaccination in Rheumatoid Arthritis Patients Receiving Disease-Modifying Antirheumatic Drugs and/or Biologics Therapy. 2019 , 25, 329-334	15
109	CD39 positive regulatory T cell frequency as a biomarker of treatment response to methotrexate in rheumatoid arthritis. 2018 , 21, 1548-1556	17
108	Immunotherapeutic Approaches of Rheumatoid Arthritis and the Implication on Novel Interventions for Refractoriness. 2018 ,	
107	Dual-functional lipid polymeric hybrid pH-responsive nanoparticles decorated with cell penetrating peptide and folate for therapy against rheumatoid arthritis. 2018 , 130, 39-47	32
106	Fabrication of a triptolide-loaded and poly- γ -glutamic acid-based amphiphilic nanoparticle for the treatment of rheumatoid arthritis. 2018 , 13, 2051-2064	33
105	Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis. 2018 , 16, 18	17
104	F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab. 2018 , 2, 6	9
103	Effects of coenzyme Q10 supplementation on matrix metalloproteinases and DAS-28 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. 2019 , 38, 3367-3374	11
102	Patterns of health care utilization of gout patients in Hawai'i-high rates of emergency department utilization as compared to rheumatoid arthritis. 2019 , 14, e0220978	0
101	Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study. 2019 , 39, 2015-2024	2
100	Anti-Arthritic Effect of Garcinol Enriched Fraction Against Adjuvant Induced Arthritis. 2019 , 13, 49-56	12
99	Chemical Composition of Bawei Longzuan Granule and Its Anti-Arthritic Activity on Collagen-Induced Arthritis in Rats by Inhibiting Inflammatory Responses. 2019 , 16, e1900294	10
98	Transdermal enhancement strategy of ketoprofen and teriflunomide: The effect of enhanced drug-drug intermolecular interaction by permeation enhancer on drug release of compound transdermal patch. 2019 , 572, 118800	10
97	Nanomedicine - advantages for their use in rheumatoid arthritis theranostics. 2019 , 316, 302-316	38
96	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. 2019 , 78, 1305-1319	61
95	Antibody-Based Biotherapeutics in Inflammatory Diseases. 2019 , 557-617	
94	Au Clusters Treat Rheumatoid Arthritis with Uniquely Reversing Cartilage/Bone Destruction. 2019 , 6, 1801671	32
93	Nawarathne Kalka: Antiinflammatory Actions and Potential Usage for Arthritic Conditions. 2019 , 323-341	

92	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). 2019 , 78, 1320-1332		65
91	Chloroquine modulates inflammatory autoimmune responses through Nurr1 in autoimmune diseases. 2019 , 9, 15559		18
90	Hyaluronic Acid Coated Acid-Sensitive Nanoparticles for Targeted Therapy of Adjuvant-Induced Arthritis in Rats. 2019 , 24,		20
89	Strategies toward rheumatoid arthritis therapy; the old and the new. 2019 , 234, 10018-10031		134
88	EULAR definition of "arthralgia suspicious for progression to rheumatoid arthritis" in a large cohort of patients included in a program for rapid diagnosis: role of auto-antibodies and ultrasound. 2020 , 39, 1493-1499		8
87	Synergistic effect of all-trans-retinal and triptolide encapsulated in an inflammation-targeted nanoparticle on collagen-induced arthritis in mice. 2020 , 319, 87-103		32
86	Comparison of the efficacy and safety of CELBESTA [®] versus CELEBREX [®] in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial. 2020 , 48, 300060520931323		
85	Comparison of the effects of Tripterygii totorum and sulfasalazine on rheumatoid arthritis: A retrospective cohort study. 2020 , 19, 421-425		1
84	Flare-up of cytokines in rheumatoid arthritis and their role in triggering depression: Shared common function and their possible applications in treatment (Review). 2021 , 14, 16		5
83	Impending radiographic erosive progression over the following year in a cohort of consecutive patients with inflammatory polyarthritis: prediction by serum biomarkers. 2020 , 6,		3
82	Transcriptional Regulation of Osteoclastogenesis: The Emerging Role of KLF2. 2020 , 11, 937		7
81	Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. 2020 , 22, 47		14
80	Efficacy and safety of peficitinib in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2020 , 30, 773-778	3-3	1
79	Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials. 2020 , 21, 1015-1025		9
78	Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis. 2021 , 87, 2014-2022		3
77	A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. <i>Modern Rheumatology</i> , 2021 , 31, 543-555	3-3	3
76	Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). <i>Modern Rheumatology</i> , 2021 , 1-16	3-3	2
75	The optimal dosage of peficitinib for the treatment of active rheumatoid arthritis: A protocol for an updated network meta-analysis. 2021 , 100, e24586		

74	Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. 2021 , 61, 429-460	13
73	Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis. 2021 , 9, e00744	
72	Polyketal Nanoparticles Co-Loaded With miR-124 and Ketoprofen for Treatment of Rheumatoid Arthritis. 2021 , 110, 2233-2240	3
71	Intra-articular use of radium dichloride ([²²³ Ra] RaCl ₂) showed relevant anti-inflammatory response on experimental arthritis model. 2021 , 1	2
70	Strategies for transdermal drug delivery against bone disorders: A preclinical and clinical update. 2021 , 336, 375-395	2
69	Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization. 2021 , 141, 2208-2218.e14	13
68	The effect of propolis supplementation on inflammatory factors and oxidative status in women with rheumatoid arthritis: Design and research protocol of a double-blind, randomized controlled. 2021 , 23, 100807	3
67	Triptertine and all-trans retinoic acid (ATRA) - loaded lipid-polymer hybrid nanoparticles for synergistic anti-arthritis therapy against inflammatory arthritis. 2021 , 49, 576-586	0
66	Monoclonal Antibodies and Antibody-Based Biotherapeutics in Inflammatory Diseases. 2013 , 393-412	1
65	Rat models of arthritis: Similarities, differences, advantages, and disadvantages in the identification of novel therapeutics. 2006 , 1-34	6
64	Minocycline-induced vasculitis fulfilling the criteria of polyarteritis nodosa. <i>Modern Rheumatology</i> , 2006 , 16, 256-9	3-3 7
63	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. <i>Modern Rheumatology</i> , 2008 , 18, 460-4	3-3 24
62	Oral administration of alpha-lipoic acid did not affect lipid peroxidation and antioxidant biomarkers in rheumatoid arthritis patients. 2019 , 89, 13-21	5
61	Organising pneumonia as the first manifestation of rheumatoid arthritis. 2011 , 2011,	9
60	Advances in the treatment of rheumatoid arthritis. 2014 , 6, 31	36
59	Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients. 2014 , 9, e108165	31
58	Histamine index and clinical expression of rheumatoid arthritis activity. 2010 , 67, 286-90	2
57	Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients. 2010 , 25, 201-6	15

- 56 Wide Applications of Chloroquine Other Than Antimalarial. **2020**, 11, 251-281 1
- 55 Effects of Atractylodis Rhizoma Alba extract on collagen-induced arthritis in mice. *The Korea Journal of Herbology*, **2012**, 27, 1-6 5
- 54 Drugs and the Musculoskeletal System. **2006**, 457-473
- 53 Future Biologic and Chemical Weapons * *The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the U.S. Army, U.S. Navy, any other U.S. military organization, or any of the places where Dr. Darling works, or any governmental organization.. **2006**, 424-433
- 52 Connective Tissue Diseases and the Heart. **2007**, 2331-2356 1
- 51 Diagnostic Significance of Anti-CCP Antibody in Korean Early Rheumatoid Arthritis. *The Journal of the Korean Rheumatism Association*, **2007**, 14, 227 2
- 50 Retinal Manifestations of the Rheumatic Diseases. **2008**, 2147-2156
- 49 Drug-Nutrient Interactions in Rheumatic Diseases. **2008**, 57-68
- 48 Monoclonal Antibodies as Therapeutic Agents. **2008**, 107-126
- 47 Drugs for inflammation and rheumatological disease. **2008**, 250-273
- 46 Hand Rheumatoid Arthritis. **2008**, 161-165
- 45 Dermatomyositis and other Autoimmune Disorders. **2009**, 731-741
- 44 A case of severe stomatitis caused by an antirheumatic drug. *Nihon Koku Geka Gakkai Zasshi*, **2009**, 55, 255-259 0.1 2
- 43 Rheumatoid Arthritis. **2009**, 1079-1084
- 42 Inflammatory Arthropathies. **2009**, 381-397
- 41 Gastrointestinal and Hepatic Manifestations of Systemic Diseases. **2010**, 557-592.e11
- 40 Recent Trend in the Treatment of Rheumatoid Arthritis. *The Journal of the Korean Orthopaedic Association*, **2010**, 45, 419 0.1 4
- 39 Disease-Modifying Antirheumatic Drug Use in Older Rheumatoid Arthritis Patients. **2011**, 151-172

20 Adalimumab in rheumatology. **2006**, 101-105

19	Radiographic progression of cervical lesions in patients with rheumatoid arthritis receiving infliximab treatment. <i>Modern Rheumatology</i> , 2010 , 20, 273-9	3.3	2
18	Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. <i>Modern Rheumatology</i> , 2013 , 23, 742-51	3.3	7
17	Dietary interventions with or without omega-3 supplementation for the management of rheumatoid arthritis: a systematic review protocol. <i>HRB Open Research</i> , 2020 , 3, 72	1.2	1
16	Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 1737-44	4.1	25
15	Intravenous pamidronate for refractory rheumatoid arthritis. <i>Journal of Research in Medical Sciences</i> , 2012 , 17, 422-7	1.6	4
14	Seven chain adaptive immune receptor repertoire analysis in rheumatoid arthritis: association to disease and clinically relevant phenotypes.		
13	Seven Chain Adaptive Immune Receptor Repertoire Analysis in Rheumatoid Arthritis: Association to Disease and Clinically Relevant Phenotypes. <i>SSRN Electronic Journal</i> ,	1	
12	Does propolis have any effect on rheumatoid arthritis? A review study.. <i>Food Science and Nutrition</i> , 2022 , 10, 1003-1020	3.2	1
11	Lactate metabolism in rheumatoid arthritis: Pathogenic mechanisms and therapeutic intervention with natural compounds.. <i>Phytomedicine</i> , 2022 , 100, 154048	6.5	1
10	Retinal Manifestations of the Rheumatic Diseases. 2022 , 4227-4262		
9	Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects.. <i>Drug Design, Development and Therapy</i> , 2022 , 16, 1365-1381	4.4	0
8	Tectoridin exhibits anti-rheumatoid arthritis activity through the inhibition of the inflammatory response and the MAPK pathway in vivo and in vitro. <i>Archives of Biochemistry and Biophysics</i> , 2022 , 727, 109328	4.1	0
7	The effect of eucalyptus inhalation on pain and the quality of life in rheumatoid arthritis. 2022 , 29, 100976		1
6	Injectable Drug Delivery Systems for Osteoarthritis and Rheumatoid Arthritis.		1
5	The prevalence of rheumatoid arthritis in Western Australia. 2022 , 6,		0
4	Genome-wide association study of methotrexate-induced liver injury in rheumatoid arthritis patients.		0
3	Therapeutic effects of kefir peptides on adjuvant-induced arthritis in rats through anti-inflammation and downregulation of matrix metalloproteinases. 2023 , 317, 121411		0

- 2 A comprehensive review of advanced drug delivery systems for the treatment of rheumatoid arthritis. **2023**, 635, 122698 ○
- 1 Phillyrin ameliorated collagen-induced arthritis through inhibition of NF- κ B and MAPKs pathways in fibroblast-like synoviocytes. **2023**, 16, 104844 ○